Entrar/Registro  
INICIO ENGLISH
 
Cirugía y Cirujanos
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Cirugía y Cirujanos >Año 2010, No. 1


Borrayo-Sánchez G, Pacheco-Bouthillier A, Mendoza-Valdez L, Isordia-Salas I, Argüero-Sánchez R, Careaga RG
Valor pronóstico de los niveles de interleucina-6 en pacientes con infarto agudo del miocardio con elevación del segmento ST
Cir Cir 2010; 78 (1)

Idioma: Español
Referencias bibliográficas: 34
Paginas: 23-30
Archivo PDF: 200.20 Kb.


Texto completo




RESUMEN

Introducción: La interlucina-6 (IL6) participa en la aterogénesis y en el fenómeno aterotrombótico más catastrófico: el infarto agudo del miocardio con elevación del ST (IAM CEST). El objetivo de esta investigación fue evaluar el pronóstico de los niveles elevados de IL6 para eventos cardiovasculares mayores en pacientes con IAM CEST.
Material y métodos: Estudiamos pacientes consecutivos con diagnóstico de IAM CEST de acuerdo con los criterios convencionales establecidos por la ACC/AHA/ESC. Se determinó IL6 sérica a las 24 horas de iniciado el evento, mediante quimioluminiscencia. Las variables de desenlace fueron arritmias, angina, falla cardiaca, reinfarto no fatal y muerte, o la combinación de ellas durante la hospitalización.
Resultados: Incluimos 97 pacientes; el punto de corte de IL6 para identificar a los pacientes con alto riesgo fue de 20 pg/ml. En el grupo I (‹ 20 pg/ml) fueron 46 pacientes y en el grupo II (› 20 pg/ml), 51 (IL6 11.52 ± 4.83 pg/ml versus 63.19 ± 44.4 pg/ml, p ‹ 0.0001). Fue más frecuente la muerte (2.2 versus 15.7 %, p = 0.023, RR 1.16 IC 95 % = 1.02-1.31) y el punto final combinado durante la hospitalización en el grupo II (21.7 versus 51 %, p = 0.003, RR = 1.59, IC 95 % = 1.16-2.19). La clase de Killip ≥ 2 y los niveles de IL6 ≥ 20 pg/ml fueron factores independientes para el punto final combinado.
Conclusiones: Los niveles de IL6 ≥ 20 pg/ml en IAM CEST se asociaron significativamente a más eventos cardiovasculares durante la hospitalización.


Palabras clave: Infarto agudo del miocardio, interleucina-6.


REFERENCIAS

  1. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365-372.

  2. Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.

  3. Muntaner J, Badimon J, Piredda, A. Placa y sangre vulnerable. Rev CONAREC 2006;86:176-182.

  4. Burke A, Virmani R. Pathophysiology of acute myocardial infarction. Med Clin North Am 2007;91:553-572.

  5. Amstrong E, Morrow D, Sabatine M. Inflammatory biomarkers in acute coronary syndromes. I: Introduction and cytokines. Circulation 2006;113:e72-e75.

  6. Amstrong E, Morrow D, Sabatine M. Inflammatory biomarkers in acute coronary syndromes. II: Acute phase reactant and biomarkers of endothelial cell activation. Circulation 2006;113:e152-e155.

  7. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.

  8. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890-1896.

  9. Levi M, Van der Poll T, Büller H. Bidirectional relation between inflammation and coagulation. Circulation 2004;109;2698-2700.

  10. Kerr R. Interleukin 6 and haemostasis. Br J Haematol 2001;115:3-12.

  11. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient. A call for new definitions and risk assessment strategies. II. Circulation 2003;108:1772-1778.

  12. Schwartz RS, Bayes-Genis A, Lesser LR, Sangiorgi M, Henry TD, Conover CA. Detecting vulnerable plaque using peripheral blood: inflammatory and cellular markers. J Interv Cardiol 2003;16:231-242.

  13. James SK, Lindahl B, Siegbahn A, Siegbahn A, Stridsberg M, Venge P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies to Open Occluded Arteries (GUSTO)-IV substudy. Circulation 2003;108:275-281. IL6 en infarto agudo del miocardio

  14. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease. JAMA 2001;286:2107 -2113.

  15. Hartford M, Wiklund O, Mattsson Hultén L, Perers E, Person A, Herlitz J, et al. CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. Int J Cardiol 2006;108:55-62.

  16. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined: a consensus of the document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-969.

  17. Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal Definition of Myocardial Infarction. Circulation 2007;116;2634-2653.

  18. Vitale C, Gebara O, Mercuro G, Wajngarten M, Silvestri A, Rossini P, et al. Value of C-reactive protein levels and IL6 in predicting levels in women at increased cardiovascular risk. Maturitas 2005;50:239-246.

  19. Ueda K, Takahashi M, Ozawa K, Kinoshita M. Decreased soluble interleukin-6 receptor in patients with acute myocardial infarction. Am Heart J 1999;138:S327-S416.

  20. Koukkunen H, Penttila K, Kemppainen A, Halinen M, Penttila I, Rantanen T, et al. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-a in the prognostic classification of unstable angina pectoris. Ann Med 2001;33:37-47.

  21. Ziakas A, Gavrilidis S, Souliou E, Giannoglou G, Stiliadis I, Karvounis H, et al. Ceruloplasmin is a better predictor of the long-term prognosis compared with fibrinogen, CRP, and IL6 in patients with severe unstable angina. Angiology 2009;60:50-59.

  22. Kucharz EJ, Wilk T. Dynamics of serum interleukin-6 level in patients with acute myocardial infarction. Eur J Intern Med 2000;115:253-256.

  23. Biasucci L, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996;94:874-877.

  24. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967;20:457-464.

  25. Ziakas A, Gavrilidis S, Giannoglou G, Souliou E, Gemitzis K, Kalampalika D, et al. In-hospital and long-term prognostic value of fibrinogen, CRP, and IL6 levels in patients with acute myocardial infarction treated with thrombolysis. Angiology 2006;57:283-293.

  26. Bonvini R, Hendiri T, Camenzind E. Inflammatory response postmyocardial infarction and reperfusion: a new therapeutic target? Eur Heart J 2005;7(suppl 1):127-136.

  27. James SK, Lindahl B, Timmer JR, Ottervanger JP, Siegbahn A, Stridsberg M, et al. Usefulness of biomarkers for predicting longterm mortality in patients with diabetes mellitus and non-ST elevation acute coronary syndromes (a GUSTO IV substudy). Am J Cardiol 2006;97:167-172.

  28. Souza JR, Oliveira RT, Blotta MH, Coelho OR. Serum levels of interleukin-6 (II-6), interlukin-18 (II-18) and C-reactive protein (CRP) in patients with type-2 diabetes and acute coronary syndrome without ST-segment elevation. Arq Bras Cardiol 2008;90:86-90.

  29. Deepa R, Velmurugan K, Arvind K, Sivaram P, Sientay C, Uday S, et al. Serum levels of interleukin-6, C-reactive protein, vascular cell adhesion molecule 1, and monocyte chemotactic protein 1 in relation to insulin resistance and glucose intolerance-the Chennai Urban Rural Epidemiology Study (CURES). Metabolism 2006;55:1232-1238.

  30. Rieusset J, Bouzakri K, Chevillotte E, Ricard N, Jacquet D, Bastard JP, et al. Suppressor of cytocine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 2004;53:2232-2241.

  31. Klover PJ, Clementi AH, Mooney Ra. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 2005;146:3417-3427.

  32. Choi KM, Lee KW, Kim SG, Kim NH, Park CG, Seo HS, et al. Inflammation, insulin resistance, and glucose intolerance in acute myocardial infarction patients without a previous diagnosis of diabetes mellitus. J Clin Endocrinol Metab 2005;90:175-180.

  33. Hedman A, Larsson PT, Alam M, Wallen NH, Nordiander R, Samad BA. CPR, IL6 and endothelin-1 levels in patients undergoing coronary artery bypass grafting. Do preoperative inflammatory parameters predict early graft occlusion and late cardiovascular events? Int J Cardiol 2007;120:108-114.

  34. Tan J, Hua Q, Gao J, Fan ZX. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clin Cardiol 2008;31:413-418.



>Revistas >Cirugía y Cirujanos >Año2010, No. 1
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019